TerminatedEUCTR 2021-006200-33

A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with A...

This historical record does not confirm current site availability.

Historical research recordFinlandAddiction

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Finland
Study phase: Phase 2

Get this study by email

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Terminated
Enrollment listed in the registry: 160
Sponsor: Clairvoyant Therapeutics Inc.
Sponsor type: Biotech company
Study type: Drug
Intervention type: Drug
Study phase: Phase 2
Locations: Finland
Age range: Not clearly listed
Official registry ID: EUCTR 2021-006200-33
Official title: Show the full official title
A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with A...

Recruitment & locations

Terminated

Finland

Registry details

Historical country statuses

Finland — Prematurely Ended

Interested in joining this study?

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Clairvoyant Therapeutics Inc.

Is this study still recruiting?

The historical registry lists this study as terminated.

Want to explore more studies?

Explore studies